Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM.

Florian Huemer; Thomas Melchardt; Bettina Jansko; Adam Wahida; Stefanie Jilg; Philipp J Jost; Eckhard Klieser; Katja Steiger; Teresa Magnes; Lisa Pleyer; Sigrun Greil-Ressler; Christoph Rass; Richard Greil; Alexander Egle

doi:10.1111/ejh.13218

Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM.

Florian Huemer (First author), Thomas Melchardt (Co-author), Bettina Jansko, Adam Wahida, Stefanie Jilg, Philipp J Jost, Eckhard Klieser (Co-author), Katja Steiger, Teresa Magnes (Co-author), Lisa Pleyer (Co-author), Sigrun Greil-Ressler (Co-author), Christoph Rass (Co-author), Richard Greil (Co-author), Alexander Egle^* (Last author)

^*Corresponding author for this work

Research output: Contribution to journal › Original Article (Journal) › peer-review

23 Citations (Web of Science)

Original language	English
Pages (from-to)	437-441
Journal	EUROPEAN JOURNAL OF HAEMATOLOGY
Volume	102
Issue number	5
DOIs	https://doi.org/10.1111/ejh.13218
Publication status	Published - 2019

Keywords

ACUTE MYELOID-LEUKEMIA
OLDER PATIENTS
OPEN-LABEL
AZACITIDINE
CELLS
DECITABINE
PROTEINS
CARE

Access to Document

10.1111/ejh.13218

Cite this

Huemer, F., Melchardt, T., Jansko, B., Wahida, A., Jilg, S., Jost, P. J., Klieser, E., Steiger, K., Magnes, T., Pleyer, L., Greil-Ressler, S., Rass, C., Greil, R., & Egle, A. (2019). Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM. EUROPEAN JOURNAL OF HAEMATOLOGY , 102(5), 437-441. https://doi.org/10.1111/ejh.13218

Huemer, Florian ; Melchardt, Thomas ; Jansko, Bettina et al. / Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM. In: EUROPEAN JOURNAL OF HAEMATOLOGY 2019 ; Vol. 102, No. 5. pp. 437-441.

@article{11db84553c064e51b81053bfb228bbf4,

title = "Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM.",

keywords = "ACUTE MYELOID-LEUKEMIA, OLDER PATIENTS, OPEN-LABEL, AZACITIDINE, CELLS, DECITABINE, PROTEINS, CARE",

author = "Florian Huemer and Thomas Melchardt and Bettina Jansko and Adam Wahida and Stefanie Jilg and Jost, {Philipp J} and Eckhard Klieser and Katja Steiger and Teresa Magnes and Lisa Pleyer and Sigrun Greil-Ressler and Christoph Rass and Richard Greil and Alexander Egle",

note = "Huemer, F; Melchardt, T; Jansko, B; Magnes, T; Pleyer, L; Greil-Ressler, S; Rass, C; Greil, R; Egle, A: Paracelsus Med Univ, Dept Internal Med Haematol Med Oncol Haemostaseol, Ctr Oncol, SCRI,LIMCR,Canc Cluster Salzburg, Salzburg, Austria; Klieser, E: Paracelsus Med Univ Salzburg, Inst Pathol, Salzburg, Austria; ",

year = "2019",

doi = "10.1111/ejh.13218",

language = "English",

volume = "102",

pages = "437--441",

journal = "EUROPEAN JOURNAL OF HAEMATOLOGY ",

issn = "0902-4441",

number = "5",

}

Huemer, F , Melchardt, T, Jansko, B, Wahida, A, Jilg, S, Jost, PJ, Klieser, E, Steiger, K, Magnes, T , Pleyer, L , Greil-Ressler, S, Rass, C, Greil, R & Egle, A 2019, 'Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM.', EUROPEAN JOURNAL OF HAEMATOLOGY , vol. 102, no. 5, pp. 437-441. https://doi.org/10.1111/ejh.13218

Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM. / Huemer, Florian (First author); Melchardt, Thomas (Co-author); Jansko, Bettina et al.
In: EUROPEAN JOURNAL OF HAEMATOLOGY , Vol. 102, No. 5, 2019, p. 437-441.

Research output: Contribution to journal › Original Article (Journal) › peer-review

TY - JOUR

T1 - Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM.

AU - Huemer, Florian

AU - Melchardt, Thomas

AU - Jansko, Bettina

AU - Wahida, Adam

AU - Jilg, Stefanie

AU - Jost, Philipp J

AU - Klieser, Eckhard

AU - Steiger, Katja

AU - Magnes, Teresa

AU - Pleyer, Lisa

AU - Greil-Ressler, Sigrun

AU - Rass, Christoph

AU - Greil, Richard

AU - Egle, Alexander

N1 - Huemer, F; Melchardt, T; Jansko, B; Magnes, T; Pleyer, L; Greil-Ressler, S; Rass, C; Greil, R; Egle, A: Paracelsus Med Univ, Dept Internal Med Haematol Med Oncol Haemostaseol, Ctr Oncol, SCRI,LIMCR,Canc Cluster Salzburg, Salzburg, Austria; Klieser, E: Paracelsus Med Univ Salzburg, Inst Pathol, Salzburg, Austria;

PY - 2019

Y1 - 2019

KW - ACUTE MYELOID-LEUKEMIA

KW - OLDER PATIENTS

KW - OPEN-LABEL

KW - AZACITIDINE

KW - CELLS

KW - DECITABINE

KW - PROTEINS

KW - CARE

U2 - 10.1111/ejh.13218

DO - 10.1111/ejh.13218

M3 - Original Article (Journal)

C2 - 30725494

SN - 0902-4441

VL - 102

SP - 437

EP - 441

JO - EUROPEAN JOURNAL OF HAEMATOLOGY

JF - EUROPEAN JOURNAL OF HAEMATOLOGY

IS - 5

ER -

Huemer F , Melchardt T, Jansko B, Wahida A, Jilg S, Jost PJ et al. Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM. EUROPEAN JOURNAL OF HAEMATOLOGY . 2019;102(5):437-441. doi: 10.1111/ejh.13218